Spero Therapeutics Inc
NASDAQ:SPRO

Watchlist Manager
Spero Therapeutics Inc Logo
Spero Therapeutics Inc
NASDAQ:SPRO
Watchlist
Price: 1.29 USD 9.32% Market Closed
Market Cap: 69.7m USD
Have any thoughts about
Spero Therapeutics Inc?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

High Profitability Stocks
Biotechnology Industry

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Spero Therapeutics Inc

Revenue
118.5m USD
Operating Expenses
-102.9m USD
Operating Income
15.6m USD
Other Expenses
1.9m USD
Net Income
17.5m USD

Margins Comparison
Spero Therapeutics Inc Competitors

Country Company Market Cap Operating
Margin
Net
Margin
US
Spero Therapeutics Inc
NASDAQ:SPRO
69.7m USD
13%
15%
US
Abbvie Inc
NYSE:ABBV
354B USD
29%
10%
US
Amgen Inc
NASDAQ:AMGN
170.3B USD
19%
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122B USD
41%
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
111.9B USD
37%
4%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
-392%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
91.3B USD
30%
34%
AU
CSL Ltd
ASX:CSL
138.4B AUD
26%
18%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
-33%
NL
argenx SE
XBRU:ARGX
32.5B EUR
-22%
-14%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
34.8B USD
-9%
-16%
Country US
Market Cap 69.7m USD
Operating Margin
13%
Net Margin
15%
Country US
Market Cap 354B USD
Operating Margin
29%
Net Margin
10%
Country US
Market Cap 170.3B USD
Operating Margin
19%
Net Margin
13%
Country US
Market Cap 122B USD
Operating Margin
41%
Net Margin
-5%
Country US
Market Cap 111.9B USD
Operating Margin
37%
Net Margin
4%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Net Margin
-392%
Country US
Market Cap 91.3B USD
Operating Margin
30%
Net Margin
34%
Country AU
Market Cap 138.4B AUD
Operating Margin
26%
Net Margin
18%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Net Margin
-33%
Country NL
Market Cap 32.5B EUR
Operating Margin
-22%
Net Margin
-14%
Country US
Market Cap 34.8B USD
Operating Margin
-9%
Net Margin
-16%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Spero Therapeutics Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Spero Therapeutics Inc
NASDAQ:SPRO
69.7m USD
26%
14%
17%
30%
US
Abbvie Inc
NYSE:ABBV
354B USD
54%
4%
16%
12%
US
Amgen Inc
NASDAQ:AMGN
170.3B USD
56%
5%
9%
10%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122B USD
-3%
-2%
25%
-84%
US
Gilead Sciences Inc
NASDAQ:GILD
111.9B USD
5%
2%
23%
13%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
91.3B USD
17%
13%
13%
16%
AU
CSL Ltd
ASX:CSL
138.4B AUD
16%
7%
12%
9%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
NL
argenx SE
XBRU:ARGX
32.5B EUR
-8%
-7%
-12%
-31%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
34.8B USD
498%
-8%
-6%
-14%
Country US
Market Cap 69.7m USD
ROE
26%
ROA
14%
ROCE
17%
ROIC
30%
Country US
Market Cap 354B USD
ROE
54%
ROA
4%
ROCE
16%
ROIC
12%
Country US
Market Cap 170.3B USD
ROE
56%
ROA
5%
ROCE
9%
ROIC
10%
Country US
Market Cap 122B USD
ROE
-3%
ROA
-2%
ROCE
25%
ROIC
-84%
Country US
Market Cap 111.9B USD
ROE
5%
ROA
2%
ROCE
23%
ROIC
13%
Country US
Market Cap 94.1B EUR
ROE
-877%
ROA
-67%
ROCE
-73%
ROIC
-182%
Country US
Market Cap 91.3B USD
ROE
17%
ROA
13%
ROCE
13%
ROIC
16%
Country AU
Market Cap 138.4B AUD
ROE
16%
ROA
7%
ROCE
12%
ROIC
9%
Country US
Market Cap 39.3B EUR
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country NL
Market Cap 32.5B EUR
ROE
-8%
ROA
-7%
ROCE
-12%
ROIC
-31%
Country US
Market Cap 34.8B USD
ROE
498%
ROA
-8%
ROCE
-6%
ROIC
-14%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top